Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.
AZD1390
ataxia telangiectasia mutated
blood-brain barrier
glioblastoma
positron emission tomography
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
12 04 2021
12 04 2021
Historique:
pubmed:
31
10
2020
medline:
21
5
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
The protein kinase ataxia telangiectasia mutated (ATM) mediates cellular response to DNA damage induced by radiation. ATM inhibition decreases DNA damage repair in tumor cells and affects tumor growth. AZD1390 is a novel, highly potent, selective ATM inhibitor designed to cross the blood-brain barrier (BBB) and currently evaluated with radiotherapy in a phase I study in patients with brain malignancies. In the present study, PET was used to measure brain exposure of 11C-labeled AZD1390 after intravenous (i.v.) bolus administration in healthy subjects with an intact BBB. AZD1390 was radiolabeled with carbon-11 and a microdose (mean injected mass 1.21 µg) was injected in 8 male subjects (21-65 y). The radioactivity concentration of [11C]AZD1390 in brain was measured using a high-resolution PET system. Radioactivity in arterial blood was measured to obtain a metabolite corrected arterial input function for quantitative image analysis. Participants were monitored by laboratory examinations, vital signs, electrocardiogram, adverse events. The brain radioactivity concentration of [11C]AZD1390 was 0.64 SUV (standard uptake value) and reached maximum 1.00% of injected dose at Tmax[brain] of 21 min (time of maximum brain radioactivity concentration) after i.v. injection. The whole brain total distribution volume was 5.20 mL*cm-3. No adverse events related to [11C]AZD1390 were reported. This study demonstrates that [11C]AZD1390 crosses the intact BBB and supports development of AZD1390 for the treatment of glioblastoma multiforme or other brain malignancies. Moreover, it illustrates the potential of PET microdosing in predicting and guiding dose range and schedule for subsequent clinical studies.
Sections du résumé
BACKGROUND
The protein kinase ataxia telangiectasia mutated (ATM) mediates cellular response to DNA damage induced by radiation. ATM inhibition decreases DNA damage repair in tumor cells and affects tumor growth. AZD1390 is a novel, highly potent, selective ATM inhibitor designed to cross the blood-brain barrier (BBB) and currently evaluated with radiotherapy in a phase I study in patients with brain malignancies. In the present study, PET was used to measure brain exposure of 11C-labeled AZD1390 after intravenous (i.v.) bolus administration in healthy subjects with an intact BBB.
METHODS
AZD1390 was radiolabeled with carbon-11 and a microdose (mean injected mass 1.21 µg) was injected in 8 male subjects (21-65 y). The radioactivity concentration of [11C]AZD1390 in brain was measured using a high-resolution PET system. Radioactivity in arterial blood was measured to obtain a metabolite corrected arterial input function for quantitative image analysis. Participants were monitored by laboratory examinations, vital signs, electrocardiogram, adverse events.
RESULTS
The brain radioactivity concentration of [11C]AZD1390 was 0.64 SUV (standard uptake value) and reached maximum 1.00% of injected dose at Tmax[brain] of 21 min (time of maximum brain radioactivity concentration) after i.v. injection. The whole brain total distribution volume was 5.20 mL*cm-3. No adverse events related to [11C]AZD1390 were reported.
CONCLUSIONS
This study demonstrates that [11C]AZD1390 crosses the intact BBB and supports development of AZD1390 for the treatment of glioblastoma multiforme or other brain malignancies. Moreover, it illustrates the potential of PET microdosing in predicting and guiding dose range and schedule for subsequent clinical studies.
Identifiants
pubmed: 33123736
pii: 5943449
doi: 10.1093/neuonc/noaa238
pmc: PMC8041329
doi:
Substances chimiques
Carbon Radioisotopes
0
ATM protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-696Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Cereb Blood Flow Metab. 2017 Mar;37(3):1095-1107
pubmed: 27207170
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1639-50
pubmed: 19437012
Neuro Oncol. 2020 Dec 18;22(12):1840-1850
pubmed: 32347934
Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):337-44
pubmed: 20102287
Nature. 2003 Jan 30;421(6922):499-506
pubmed: 12556884
J Cereb Blood Flow Metab. 1989 Oct;9(5):696-708
pubmed: 2528555
Sci Rep. 2019 Mar 29;9(1):5308
pubmed: 30926941
J Neurooncol. 2017 May;132(3):427-432
pubmed: 28290001
J Pharmacol Exp Ther. 1996 Oct;279(1):325-31
pubmed: 8859010
J Cereb Blood Flow Metab. 2020 Apr;40(4):799-807
pubmed: 31006308
Cancer. 2010 Jan 15;116(2):302-8
pubmed: 19937674
Mol Cancer Ther. 2012 Oct;11(10):2183-92
pubmed: 22891038
Drug Metab Dispos. 2011 Jul;39(7):1270-7
pubmed: 21474681
Nat Rev Drug Discov. 2003 Mar;2(3):233-40
pubmed: 12612650
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
EJNMMI Res. 2015 Apr 30;5:30
pubmed: 25977884
Nucl Med Biol. 1999 Jul;26(5):509-18
pubmed: 10473189
Clin Pharmacokinet. 2011 Feb;50(2):111-20
pubmed: 21142292
Cancer Res. 2015 Oct 15;75(20):4416-28
pubmed: 26282173
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
CNS Drugs. 2017 Feb;31(2):109-133
pubmed: 28101766
Neuro Oncol. 2018 Mar 27;20(4):435-436
pubmed: 29538691
Drug Metab Dispos. 2009 Jun;37(6):1226-33
pubmed: 19299522
Sci Adv. 2018 Jun 20;4(6):eaat1719
pubmed: 29938225
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
J Cereb Blood Flow Metab. 2015 Sep;35(9):1485-93
pubmed: 25873425
Trends Pharmacol Sci. 2006 Jun;27(6):310-6
pubmed: 16678917
Anal Bioanal Chem. 2013 Feb;405(4):1303-10
pubmed: 23180082
J Clin Invest. 2014 Aug;124(8):3289-91
pubmed: 25036714
Neuroimage. 2014 Jan 1;84:342-53
pubmed: 23994452
J Comput Assist Tomogr. 1981 Feb;5(1):136-41
pubmed: 6972391
J Nucl Med. 2009 May;50(5):807-13
pubmed: 19372478
Science. 1998 May 15;280(5366):1089-91
pubmed: 9582124
Int J Neuropsychopharmacol. 2015 Mar 26;18(10):pyv036
pubmed: 25813017
Int J Neuropsychopharmacol. 2013 Jul;16(6):1231-9
pubmed: 23217964
Pharmacol Ther. 2019 Nov;203:107391
pubmed: 31299316
Bioorg Med Chem Lett. 2013 Oct 1;23(19):5415-20
pubmed: 23978650
Ann Neurol. 1984 Mar;15(3):217-27
pubmed: 6609679
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
Cephalalgia. 2005 Dec;25(12):1103-9
pubmed: 16305598
Drug Discov Today. 2019 May;24(5):1067-1073
pubmed: 30710641
Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66
pubmed: 12937873
Pharm Res. 2008 Aug;25(8):1737-50
pubmed: 18058202
J Neurochem. 1992 Jun;58(6):2303-10
pubmed: 1573409